Clinical trials: Eye Diseases, Hereditary
Thyroid Eye Disease, TED, Graves Orbitopathy
Study to Assess Linsitinib in Participants With Moderate to Severe Active Thyroid Eye Disease (TED)
The goal of this clinical trial is to evaluate the efficacy, safety, and tolerability of linsitinib in participants with moderate to severe Thyroid Eye Disease (TED).
- Trial name
- ORBIT (NCT07753603)
- Testing
- linsitinib
- Where
- 18 sites in United States
- Volunteers
- 130 people
- Sponsor
- Sling Therapeutics, Inc.
Fuchs' Endothelial Dystrophy
Supine Positioning for Graft Attachment After Descemet Membrane Endothelial Keratoplasty
This randomized controlled trial evaluates the efficacy and safety of postoperative supine head positioning on graft attachment after Descemet membrane endothelial keratoplasty in patients with Fuchs' endothelial corneal…
- Trial name
- SUPER-DMEK (NCT05399095)
- Testing
- Supine positioning: 5 days, Supine positioning: 1 days
- Where
- Germany
- Volunteers
- 90 people
- Sponsor
- University Eye Hospital, Freiburg
Thyroid Eye Disease (TED), Graves' Disease
Evaluation of ETHY-001 for Safety, Tolerability, and Clinical Activity in Thyroid Eye Disease
The primary objective of study is to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ETHY-001 in healthy volunteers and participants with Thyroid Eye Disease after single subcutaneous doses.
- Conditions
- Thyroid Eye Disease (TED), Graves' Disease, Eye Diseases, Hereditary, Eye Diseases
- Trial name
- NCT07885605
- Testing
- ETHY-001
- Where
- 3 sites in United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Ethyreal Bio, Inc.
Choroideremia, X-Linked Retinitis Pigmentosa
Long-term Safety and Efficacy Follow-up of BIIB111 for the Treatment of Choroideremia and BIIB112 for the Treatment of X-Linked Retinitis Pigmentosa
The objective of the study is to evaluate the long-term safety and efficacy of a sub-retinal injection of BIIB111 in participants with Choroideremia (CHM) who have been previously treated with BIIB111 and who have exited an…
- Trial name
- SOLSTICE (NCT03584165)
- Testing
- BIIB111, BIIB112
- Where
- 25 sites in United States, Brazil and 7 more
- Volunteers
- 277 people
- Sponsor
- NightstaRx Ltd, a Biogen Company
Intellectual Disability, Rubinstein-Taybi Syndrome
Functional Tests to Resolve Unsolved Rare Diseases. Rares.
Rares diseases are a heterogeneous group of conditions which need important tools for diagnosis. The use of high-throughput sequencing is able to diagnose half of the patients.
- Conditions
- Intellectual Disability, Rubinstein-Taybi Syndrome, Cystic Fibrosis, Congenital Heart Defect
- Trial name
- RID (NCT05696912)
- Testing
- Ex-vivo approach concerning 25 patients, In-vitro approach concerning 25 patients
- Where
- France
- Volunteers
- 50 people
- Sponsor
- University Hospital, Bordeaux
Retinitis Pigmentosa
Exercise and RP (AVAMC and Emory)
The purpose of this study is to look in humans at the relationship between moderate or little exercise and their potential effects on the retina in patients with Retinitis Pigmentosa (RP).
- Trial name
- NCT03381235
- Testing
- Spin exercise
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Emory University
Injury Brain, Eye Abnormalities
Reading Problems Associated With Central Nervous System (CNS) Pathologies.
This project aims to analyse eye movements, their alterations and influence in reading performance in patients with acquired CNS diseases and compare them with people of the same age, without neurological or ocular pathology and…
- Conditions
- Injury Brain, Eye Abnormalities, Multiple Sclerosis, Parkinson Disease
- Trial name
- NCT04937725
- Testing
- eye tracking
- Where
- Spain
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA
Bullous Keratopathy, Corneal Erosion
Air Optix® Night and Day® Aqua Therapeutic Wear
The purpose of this study is to support the safety and performance assessment of Air Optix Night and Day Aqua (AONDA) soft contact lenses for therapeutic use in accordance with updated EU Medical Device Regulation (MDR)…
- Conditions
- Bullous Keratopathy, Corneal Erosion, Entropion, Corneal Edema
- Trial name
- NCT05956535
- Testing
- Lotrafilcon A contact lenses, Balafilcon A contact lenses
- Where
- 3 sites in United States
- Volunteers
- 168 people
- Sponsor
- Alcon Research
Thyroid Eye Disease
A Study of Teprotumumab N01 in Subjects With Active Thyroid Eye Disease
This is a multicenter, randomized, open-label, active-controlled Phase IV clinical trial in participants with active thyroid eye disease (TED).
- Trial name
- NCT07265258
- Testing
- Teprotumumab N01, Methylprednisolone
- Where
- China
- Volunteers
- 92 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Retinopathy of Prematurity
Lucentis to Treat Retinopathy of Prematurity (ROP) 3 Plus Disease
Retinopathy of prematurity (ROP) is a neovascular retinal disorder of premature born children, characterized by the development of retinal neovascularisation, macular dragging and eventually retinal detachment.
- Trial name
- NCT02164604
- Testing
- intravitreal injection of 0.03ml ranibizumab
- Where
- Switzerland
- Volunteers
- 6 people
- Sponsor
- Kantonsspital Aarau
Graves Ophthalmopathy, Thyroid Associated Ophthalmopathy
Treatment of Graves´ophthalmopathy with Simvastatin (GO-S)
In an investigator initiated multicenter trial (Malmö, Odense, Århus) the investigators aim at evaluating activity of Graves´ophthalmopathy (GO) and progress to severe GO in patients with mild to moderate Graves´ ophthalmopathy…
- Conditions
- Graves Ophthalmopathy, Thyroid Associated Ophthalmopathy, Thyroid Associated Orbitopathy
- Trial name
- NCT03131726
- Testing
- Simvastatin 40mg
- Where
- Sweden
- Volunteers
- 80 people
- Sponsor
- Lund University
Anesthesia, Intraocular Pressure
Establishment of an Anaesthetic Protocol for Examinations for Children With Glaucoma or Suspected Glaucoma
Correct measurement of the intraocular pressure of children with glaucoma or suspected glaucoma is essential for diagnosis and therapy.
- Conditions
- Anesthesia, Intraocular Pressure, Glaucoma, Suspect, Pediatric Glaucoma
- Trial name
- eyeBIS (NCT03972852)
- Where
- Germany
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Johannes Gutenberg University Mainz
Sturge Weber Syndrome
Adjunctive Everolimus (RAD 001) Therapy for Epilepsy in Children With Sturge-Weber Syndrome (SWS)
Sturge Weber Syndrome (SWS) is a rare disease that affects the patient's brain and causes benign (non-cancerous) tumors to grow in the brain. One of the symptoms of SWS is epilepsy. People with epilepsy have seizures.
- Trial name
- NCT01997255
- Testing
- Everolimus
- Where
- United States
- Sponsor
- Baylor College of Medicine
Leber's Hereditary Optic Neuropathy (LHON)
Evaluation of Impact of Disease and Visual Disability on Quality of Life and Loss of Independence of Patients Living in France With Leber's Hereditary Optic Neuropathy (LHON) Through Qualitative and Quantitative Data Collection
Leber's hereditary optic neuropathy (LHON) is a rare mitochondrial genetic disorder characterized by optic nerve atrophy due to the degeneration of retinal ganglion cells, which leads to acute visual loss.
- Trial name
- NCT05555784
- Where
- France
- Volunteers
- 12 people
- Sponsor
- Argo Sante
Retinopathy of Prematurity
Bevacizumab Treatment For Type 1 ROP
Type 1 retinopathy of prematurity in zone I represents the most severe type of ROP and has the worst prognosis. It is unknown whether low-dose bevacizumab will be successful in these severe cases.
- Trial name
- ROP4 (NCT04634578)
- Testing
- Bevacizumab
- Where
- 26 sites in United States, Canada
- Volunteers
- 77 people
- Sponsor
- Jaeb Center for Health Research
Frailty, Vision and Hearing Loss
Health Determinants in Older Adults Living At Home
The observational study will conduct interprofessional assessments by registered nurses, physiotherapists, and occupational therapists of health determinants (i.e., frailty, physical, cognitive, and sensory function, mental and…
- Conditions
- Frailty, Vision and Hearing Loss, Cognitive Function, Social 1, Mental Health Issue
- Trial name
- NCT05837728
- Testing
- Health promoting assessment of older adults living at home
- Where
- Norway
- Volunteers
- 40 people
- Sponsor
- University of Stavanger
Rhinitis, Allergic, Asthma, Allergic
Food-specific IgG4-guided Elimination Diets Improve Allergy Symptoms in Children
Allergic diseases in children are major public health concerns due to their widespread and rising prevalence. The most classic pathway to trigger allergy is type I allergy mediated by immunoglobulin E(IgE), but the role of…
- Conditions
- Rhinitis, Allergic, Asthma, Allergic, Conjunctivitis, Allergic, Atopic Dermatitis
- Trial name
- NCT06063044
- Where
- China
- Volunteers
- 407 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
SCID, Omenn's Syndrome
Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies
This is a standard of care treatment guideline for allogeneic hematopoetic stem cell transplant (HSCT) in patients with primary immune deficiencies.
- Conditions
- SCID, Omenn's Syndrome, Reticular Dysgenesis, Wiskott-Aldrich Syndrome
- Trial name
- NCT01652092
- Testing
- Alemtuzumab 0.3 mg, Cyclophosphamide, Busulfan
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Retinopathy of Prematurity (ROP)
Comparing Alternative Ranibizumab Dosages for Safety and Efficacy in Retinopathy of Prematurity
This study is designed as an exploratory study to assess safety and efficacy of two different doses of the anti-VEGF agent ranibizumab (0.12 mg vs. 0.20 mg) in the treatment of infants with retinopathy of prematurity.
- Trial name
- CARE-ROP (NCT02134457)
- Testing
- ranibizumab
- Where
- 9 sites in Germany
- Volunteers
- 19 people
- Sponsor
- University Hospital Freiburg
Retinitis Pigmentosa, Choroideremia
A Phase I/II Dose-escalating Study of the Safety, Tolerability and Efficacy of KIO-301 Administered Intravitreally to Patients With Retinitis Pigmentosa and Choroideremia (ABACUS)
A phase I/II dose-escalating study of the safety, tolerability and efficacy of KIO-301 administered intravitreally to patients with retinitis pigmentosa and choroideremia (ABACUS).
- Conditions
- Retinitis Pigmentosa, Choroideremia, Non-Syndromic Rod-Dominant Inherited Retinal Diseases
- Trial name
- NCT05282953
- Testing
- KIO-301
- Where
- 3 sites in Australia
- Volunteers
- 32 people
- Sponsor
- Kiora Pharmaceuticals, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.